Product Description
Idorsia is developing Lucerastat as a treatment for Fabry disease. (Sourced from: https://www.idorsia.com/media/news-details?newsId=2608540)
Mechanisms of Action: GCS Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Canada, France, Germany, Japan, Netherlands, Norway, Poland, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Fabry Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03737214 |
ID-069A302 | P3 |
Active, not recruiting |
Fabry Disease |
2029-08-01 |
49% |
2025-06-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2024-513884-20-00 |
ID-069A302 | P3 |
Recruiting |
Fabry Disease |
2027-11-23 |
49% |
2025-05-02 |
Treatments |
jRCT2080224890 |
jRCT2080224890 | P3 |
Completed |
Fabry Disease |
2024-03-31 |